Results 151 to 160 of about 42,251 (222)

RETRACTED: Batool et al. Development and Evaluation of Cellulose Derivative and Pectin Based Swellable pH Responsive Hydrogel Network for Controlled Delivery of Cytarabine. <i>Gels</i> 2023, <i>9</i>, 60. [PDF]

Gels
Batool N, Sarfraz RM, Mahmood A, Rehman U, Zaman M, Akbar S, Almasri DM, Gad HA.   +7 more
europepmc   +1 more source

Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML. [PDF]

Clin Case Rep
Silva-Bermudez LS, Streuer A, Christodoulou F, Eisele P, Steiner L, Metzgeroth G, Platten M, Hofmann WK, Abba ML.   +8 more
europepmc   +1 more source

Systemic Toxicity Profile of Chemotherapeutic Agents in a Wistar Rat Model: A Preliminary Report. [PDF]

J Toxicol
Kathare J, Mbaria J, Kaluwa C, Mapenay I, Moriasi G.   +4 more
europepmc   +1 more source

Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse. [PDF]

Leuk Res Rep
Bouhoula D, Regaieg H, Abroug H, Sayed NB, Youssef YB.   +4 more
europepmc   +1 more source

Neuromyelitis Optica Spectrum Disorder in a Pediatric Patient Following Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. [PDF]

Blood Cell Ther
Seregin GZ, Vitalievna Bronina N, Andreevich Burtsev E, Maksutovich Kurmanov B, Vsevolodovna Lifshits A, Olegovich Bronin G.   +5 more
europepmc   +1 more source

Bilateral proptosis as the first manifestation in a patient with acute myeloid leukemia: Case report. [PDF]

Medicine (Baltimore)
Edrees R, Hazeem M, Kheder M.
europepmc   +1 more source

A rare case of variant acute promyelocytic leukemia with <i>FIP1L1-RARA</i> fusion gene: case report and literature review. [PDF]

Leuk Res Rep
Qiu Y, Zhou H, Wang S.
europepmc   +1 more source

The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review. [PDF]

Ther Adv Med Oncol
Kowalczyk A, Zarychta J, Zawitkowska J, Lejman M.   +3 more
europepmc   +1 more source

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia. [PDF]

Br J Haematol
Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Chumnumsiriwath P, Ciurea SO, Ramos-Perez J, Bellman P, Jeyakumar D, Kongtim P, Naqvi K.   +11 more
europepmc   +1 more source